ORLANDO, FL / ACCESSWIRE / June 27, 2019 / LightPath Technologies, Inc. (NASDAQ: LPTH) (“LightPath,” the “Company,” or “we”), a leading vertically integrated global manufacturer, distributor and integrator of proprietary optical and infrared components and high-level assemblies, today announced it has been awarded a $1.9 million order for 19mm and 24mm infrared (“IR”) lens assemblies from a North American manufacturer. The IR optics will be manufactured from LightPath’s proprietary Black Diamond™ (“BD6”) infrared material. The finished lenses will be used in products sold into the consumer marketplace, including sporting, hunting, and outdoor recreational applications.

“We are pleased to announce our third and largest order to date for BD6 lenses from a major North American sporting goods and outdoor products original equipment manufacturer,” said Jim Gaynor, President and Chief Executive Officer of LightPath. “This order reflects some of the increasing demand we are experiencing for our BD6 line of products. Lens assemblies for this contract will be produced and shipped over a 12-month period beginning July 2019. LightPath’s recently upgraded and increased volume production capacity enables streamlined delivery and ample room for growth from new and existing customers.”

LightPath’s proprietary BD6 thermal imaging lenses and related assemblies are produced using the Black Diamond™ chalcogenide-based glass compound developed and grown internally by LightPath. The Company’s new BD6 chalcogenide line of infrared lenses are more malleable, contain no rare earths, and are lighter and less expensive to manufacture in terms of material and handling as compared with products made from germanium. Chalcogenide glass material is inherently optically athermal in addition to offering great transmission over a very wide range of temperature, making it ideal for diversified uses. LightPath is well-positioned with a robust product suite that is increasingly being sought after for a variety of thermal imaging, sensory and measurement applications ranging in effective focal lengths of 1.3mm to over 100mm. Commercial applications for BD6 lenses include cameras and other sporting and outdoor products designed for search and rescue, thermal imaging assemblies for low cost sensors, nature observation, hunting, maritime navigation and other applications.

About LightPath Technologies

LightPath Technologies, Inc. (NASDAQ: LPTH) is a leading global, vertically integrated provider of optics, photonics and infrared solutions for the industrial, commercial, defense, telecommunications, and medical industries. LightPath designs, manufactures, and distributes proprietary optical and infrared components including molded glass aspheric lenses and assemblies, infrared lenses and thermal imaging assemblies, fused fiber collimators, and proprietary Black Diamond™ (“BD6”) chalcogenide-based glass lenses. LightPath also offers custom optical assemblies, including full engineering design support. The Company is headquartered in Orlando, Florida, with manufacturing and sales offices in Latvia and China.

LightPath’s wholly-owned subsidiary, ISP Optics Corporation, manufactures a full range of infrared products from high performance MWIR and LWIR lenses and lens assemblies. ISP’s infrared lens assembly product line includes athermal lens systems used in cooled and un-cooled thermal imaging cameras. Manufacturing is performed in-house to provide precision optical components including spherical, aspherical and diffractive coated infrared lenses. ISP’s optics processes allow it to manufacture its products from all important types of infrared materials and crystals. Manufacturing processes include CNC grinding and CNC polishing, diamond turning, continuous and conventional polishing, optical contacting and advanced coating technologies.

For more information on LightPath and its businesses, please visit www.lightpath.com.

Forward-Looking Statements

This news release includes statements that constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our ability to expand our presence in certain markets, future sales growth, continued improvements in our financial results,and implementation of new distribution channels. This information may involve risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, factors detailed by LightPath Technologies, Inc. in its public filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. Except as required under the federal securities laws and the rules and regulations of the Securities and Exchange Commission, we do not have any intention or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

###

Investor Relations Contact:

Jordan Darrow
Darrow Associates
512-551-9296
jdarrow@darrowir.com

SOURCE: LightPath Technologies, Inc.

ReleaseID: 549893

VANCOUVER, BC / ACCESSWIRE / June 27, 2019 / EastWest Bioscience (the “Company” or “EastWest”) (TSX.V: EAST) announces that its subsidiary EastWest Science USA has signed a mutual distributor agreement with GM Health Wholesale (“GM Health”) (www.gmhempco.com), a Kentucky company and a leading manufacturer and wholesaler of CBD Tinctures, Creams, Salves and Capsules. Under the terms of this agreement GM Health will become a distributor of EastWest’s products and EastWest will become a global distributor for GM Health’s all-natural CBD products.

“EastWest is excited to be associating themselves with experts in the field of CBD extracts and hemp cultivation. GM Health’s products will add significant value to EastWest’s offering” says Rodney Gelineau, CEO of EastWest Bioscience Inc. “And we’re proud that GM Health will be adding EastWest’s +CBD products, currently Natural Pet Science, to their wholesale catalogue.” Gelineau continues.

The addition of GM Health’s products to EastWest’s CBD catalogue greatly accelerates time to market for several products and introduces new and unique distribution channels via GM Health’s network of independent pharmacies stretching throughout multiple states.

GM Health’s production operates from a 90,000 square foot USDA accredited facility with plans to expand to 360,000 square feet of greenhouse by the end of 2020. Their high CBD hemp clones, offered by Grundy Hemp Co, typically contain 10-17% CBD content and include Uno, Dos, Tres, and The Wife strains, from their own breeding program.

GM Health’s hemp extract is the first naturally extracted oil on the market which is completely free of chlorophylls and carbonic acid. Using a patented flash activated process allows the plants natural terpene profile to be preserved with the true spectrum of cannabinoids, leaving a neutral nutty, sweet flavour which is barely noticeable and mixes well into all food products and nutritional supplements.

The agreement is effective as of June 26th 2019 and continues until terminated.

About EastWest Bioscience Group

EastWest Bioscience is a vertically-integrated wellness company with the infrastructure to become a global giant in the Hemp & CBD consumer health market. Since it was founded in 2016, EastWest continues to grow as a high-quality producer, manufacturer and distributor of multiple lines of premium health and hemp products. EastWest currently has more than 200+ NPN’s in its stable of products.

EastWest’s consumer product lines are divided into four distinct brands: 1) Natural Advancement – natural biopharmaceutical health supplements; 2) Earth’s Menu – all-natural hemp superfoods; 3) Natural Pet Science – pet food and pet supplements; and 4) ChanvreHemp – all-natural health and beauty products.

In Canada, EastWest has a 34,000 Sq. Ft, Health Canada-licensed, GMP (Good Manufacturing Practices) – certified manufacturing facility and produces premium nutraceutical brands, offering natural products for a preventive care lifestyle. EastWest and Benchmark Botanicals (BBT-CSE) also have a Joint Venture Intent to accelerate acquisition of Processor, Analytical and Research and Development licenses under the Cannabis Act in EastWest’s Penticton facility. These three classes of the Cannabis Act license will allow Benchmark and EastWest to build out an extensive extraction, laboratory, and research facility at EastWest’s Health Canada Certified facility.

In the USA, EastWest USA has entered into a Joint Venture with Azema Sciences, securing for EastWest first rights on Azema’s output of bulk CBD and finished CBD products manufactured, and which are ready for sale in the USA and globally. EastWest Science USA (“EastWest USA”), EastWest’s US operating division, will be the preferred distributor for Azema’s finished goods. These finished products will include CBD creams, tinctures and salves which are products not currently in EastWest’s catalogue. Additionally, EastWest will have first right of refusal to all potential opportunities relating to Azema’s Kentucky based CBD processing facility. EastWest currently has TSX Approval for sale of its consumer products in 21 US States.

About GM Health Wholesale

GM Health Wholesale was formed in early 2018 to carry the retail side of its production partnership. GM Health Wholesale is a company focused on the highest degree of honesty, integrity, and superior quality with a zero-waste policy for the betterment of the hemp industry. We are vertically integrated from cell to sell and we stay with you all the way.

Jay Grundy, Co-Founder of GM Health Wholesale, LLC, has over 15 years of entrepreneurial success in real estate, retail sales, and most recently in the world of hemp. He is involved is all aspects of hemp including the extraction and sale of oils, indoor greenhouse and outdoor production of cannabis, and the brokerage of domestic hemp bio-mass throughout the US.

Ben Mudd, Co-Founder of GM Health Wholesale, LLC, graduated from the University of Kentucky College of Pharmacy in 2012 and is a practicing pharmacist at an independent pharmacy in central Kentucky. Ben uses his knowledge in pharmaceuticals to promote our premium products in multiple independent pharmacies throughout the US. He has become extremely knowledgably in the world of CBD giving input on new formulations and applications of these products.

ON BEHALF OF THE BOARD OF DIRECTORS
EASTWEST BIOSCIENCE GROUP

“Rodney Gelineau”
Co-Founder, Chief Executive Officer and Director

TSXV – Symbol: EAST

Company Website: www.eastwestbioscience.com
Contact: Nicholas Vincent – Investor Relations on 1-800-409-1930 or investors@eastwestscience.com.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the terms and conditions of the Acquisition. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; and delay or failure to receive board, shareholder or regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: EastWest Bioscience Group

ReleaseID: 550084

FISHERS, IN / ACCESSWIRE / June 27, 2019 / American Resources Corporation (NASDAQ: AREC), a supplier to the rapidly growing global infrastructure marketplace, with a primary focus on the extraction, processing, transportation, and distribution of metallurgical coal to the steel industry, is excited to announce the hiring of Andy Cox as the company’s Director of Coal Sales. In this new role for the company, Mr. Cox will oversee all sales of the company’s metallurgical, specialty, industrial and high-quality thermal coals to existing customers while developing new sales strategies and partnerships throughout the industry.

Andy joins American Resources with over three decades of coal sales experience. Most recently, he worked in coal marketing and sales with Wise Energy Group, and prior to that he was Vice President of Marketing and Sales at Murray Energy Corporation for nearly five years. Before Murray Energy, he worked as Vice President of Sales for Rhino Resource Partners for nearly seven years.

This position at American Resources is a newly created role that is in response to the company’s rapid coal production growth and its anticipated continued increase of coal sales. The forecasted increase in production of high quality metallurgical coal (or coking coal) and pulverized coal injection (PCI) coal over the next eighteen months will be sold to the international and domestic marketplaces.

The appointment of Mr. Cox supports the Company’s strategic growth as a low-cost producer of metallurgical coal to serve steel producers and infrastructure initiatives worldwide. Chief Executive Officer of American Resources, Mark Jensen noted: “We are thrilled to have someone of Andy’s caliber, character and work ethic join our team and his hiring comes at a time where we are forecasting rapid growth over the next four quarters.. We continue to see numerous opportunities to expand both organically and through strategic acquisitions and want to be more proactive in expanding our distribution network and servicing our customer base. Andy brings extensive knowledge and relationships to our platform which will certainly complement our growth.”

“I am excited to join American Resources Corporation in their endeavor as they continue to expand their operations and coal production” commented Andy Cox. “After understanding their production strategy and growth potential, I think I can add value to the team as the company executes on its growth.”

American Resources Corporation continues to focus on its growth objective by efficiently leveraging its large number of core mining permits and through identifying strategic, supplemental acquisitions. The Company is committed to being one of the lowest cost operators in the Central Appalachian basin (CAPP) and throughout all its coal mining, processing, and transportation operations.

Andy can be reached at awc@questenergyinc.com or by phone at (434) 409-5208.

About American Resources Corporation

American Resources Corporation is a supplier of raw materials to the rapidly growing global infrastructure marketplace. The company’s primary focus is on the extraction, processing, transportation and selling of metallurgical coal and pulverized coal injection (PCI) to the steel industry. AREC’s operations are based in the Central Appalachian basin of eastern Kentucky and southern West Virginia, where premium quality metallurgical products are located.

The company’s business model is based on running a streamlined and efficient operation to economically extract and deliver resources to meet its customers’ demands. By running operations with low or no legacy costs, American Resources Corporation works to maximize margins for its investors while being able to scale its operations to meet the growth of the global infrastructure market.

Website:

http://www.americanresourcescorp.com

Institutional/Retail/Individual Contact:

American Capital Ventures
Howard Gostfrand, President
305-918-7000 – Office
hg@amcapventures.com
www.amcapventures.com

PCG Advisory
Jeff Ramson, CEO
646-863-6893
jramson@pcgadvisory.com
www.pcgadvisory.com

Company Contact:

Mark LaVerghetta
317-855-9926 ext. 0
Vice President of Corporate Finance and Communications
investor@americanresourcescorp.com

Special Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that could cause the Company’s actual results, performance, or achievements or industry results to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. These statements are subject to a number of risks and uncertainties, many of which are beyond American Resources Corporation’s control. The words “believes”, “may”, “will”, “should”, “would”, “could”, “continue”, “seeks”, “anticipates”, “plans”, “expects”, “intends”, “estimates”, or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Any forward-looking statements included in this press release are made only as of the date of this release. The Company does not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent events or circumstances. The Company cannot assure you that the projected results or events will be achieved.

SOURCE: American Resources Corporation

ReleaseID: 550085

No Device Failures in Eight Test Subjects

IRVINE, CA / ACCESSWIRE / June 27, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today provided an update on the status of its CoreoGraft animal feasibility study. There have been no device failures in eight animal test subjects where CoreoGrafts have been implanted as heart bypass grafts, with one group observed at 30 days, and another group observed at 45 days post-surgery. In particular, the CoreoGrafts have showed no signs of thrombosis, aneurysmal degeneration, neointimal hyperplasia, stenosis, changes in the lumen, or other problems that are known to plague saphenous vein grafts (“SVGs”) and attempts by others to create small caliber (3 mm and 4 mm) grafts.

Dr. Marc H. Glickman, Hancock Jaffe’s Chief Medical Officer stated, “Overall, the CoreoGrafts have performed very well throughout our feasibility study. I was particularly surprised how pristine some of our CoreoGrafts looked at 45 days, especially in light of the difficulties that others have experienced when attempting to create small caliber grafts. Our early success is extremely encouraging, and we have not seen anything to dissuade our belief that the CoreoGraft will be a viable product.”

HJLI has been conducting a series of experimental acute (shorter-term) and chronic (longer-term) animal feasibility studies to evaluate the safety and performance of the CoreoGraft and the procedures to implant the CoreoGraft under a variety of conditions. The challenges of animal feasibility studies include technical challenges related to implantation surgical procedures, and anatomical challenges related to the animal test subjects, primarily due to physiological and anatomical differences in the animal test subjects versus humans. The knowledge HJLI gains from the animal feasibility study will be valuable in finalizing device design and in developing required GLP study designs for FDA approval submissions.

HJLI expects to add two additional animal test subjects to the feasibility study, testing different implantation techniques. The remaining animals in the feasibility study that were observed at 45 days will be observed again at 90 days post-surgery. Hancock Jaffe will provide the next CoreoGraft update at that time. With anticipated positive results at 90 days, HJLI plans to initiate a dialogue with the FDA to discuss regulatory approval plans. HJLI expects the next studies after the feasibility study to be a GLP studies, where the studies are conducted in accordance with standards and guidelines acceptable for FDA submissions.

HJLI’s CoreoGraft is a potential alternative to using saphenous vein grafts (“SVGs”) to revascularize the heart during coronary artery bypass graft (“CABG”) surgeries. The current standard of care for most CABG surgeries is to harvest the saphenous vein from the leg of the patient. SVGs are known to have high short term and long-term failure rates when used as grafts around the heart. Studies indicate that up to 40% of SVGs fail within one year of CABG surgeries, with a significant percentage failing within the first 30 days. Eight to ten years after surgery, SVG failure rates are known to be in as high as 75%. In addition to high SVG failure rates, the SVG harvest procedure itself is invasive, painful, and subject to complication rates exceeding 20%. The CoreoGraft is being developed for bypass patients where SVG harvest is not an option and to potentially replace SVGs. Lower failure and complication rates would be advantageous to both doctors and patients, and would lower the overall costs associated with CABG surgeries.

About Hancock Jaffe Laboratories, Inc.

HJLI specializes in developing and manufacturing bioprosthetic (tissue based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValve®, a porcine based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency; and the CoreoGraft®, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery. For more information, please visit HancockJaffe.com.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of Hancock Jaffe Laboratories, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, with respect to our first-in-human VenoValve study) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

CONTACT:

HJLI Press Contacts:

Amy Carmer
Tel: 949-261-2900
Email: ACarmer@HancockJaffe.com

Media & Investor Relations Contact:

MZ North America
Chris Tyson
Managing Director
(949) 491-8235
HJLI@mzgroup.us
www.mzgroup.us

SOURCE: Hancock Jaffe Laboratories, Inc.

ReleaseID: 550032

Company Sees over 200% Quarter-Over-Quarter Revenue Increase in Illinois and Michigan from Q1 to Q2

GARDEN GROVE, CA / ACCESSWIRE / June 27, 2019 / KushCo Holdings, Inc. (OTCQX: KSHB) (”KushCo” or the ”Company”), announced the development of a new 40,000 square foot distribution facility in Taylor, Michigan. The new facility will support the Company’s rapidly growing operations across the Midwest, including Illinois and Michigan, which both recently legalized recreational cannabis.

The facility will serve as the Company’s anchor in the Midwest and will include a show room, sampling room and office space for sales and operations teams. With states like Michigan, Illinois and Missouri entering into medical and recreational markets, the new facility will optimize operational efficiencies and enable KushCo to grow customer relationships in the Midwest region.

“We’re excited to invest in the infrastructure to support these key markets with boots on the ground in the Midwest and the launch of our new distribution facility in Michigan. This new initiative will expand our footprint and deepen our relationships with operators in the region,” said Nick Kovacevich, CEO of KushCo Holdings. “Our 215% quarter-over-quarter growth in Michigan is a testament to the potential in the region and our ability to remain a valued partner in the most promising recreational and medical markets across the United States.”

Jason Vegotsky, the Company’s Chief Revenue Officer, added, “Illinois is a particularly important market for us given our relationships with key MSOs headquartered there, and our investments are already paying off with new customers being onboarded to our platform. An essential aspect of our aggressive expansion strategy is our commitment to strategic investments in regions throughout the country as the legal structure supporting cannabis continues to evolve.”

To be added to the distribution list, please email ir@kushco.com with ”Kush” in the subject line.

About KushCo Holdings

KushCo Holdings, Inc. (OTCQX: KSHB) (www.kushco.com) is the premier producer of ancillary products and services to the cannabis and hemp industries. KushCo Holdings’ subsidiaries and brands provide, product quality, exceptional customer service, compliance knowledge and a local presence in serving its diverse customer base.

Founded in 2010, KushCo Holdings has now sold more than 1 billion units to growers, processors and producers across North America, South America, and Europe.

The Company has been featured in media nationwide, including CNBC, Los Angeles Times, TheStreet.com, Entrepreneur, and Inc. Magazine. While KushCo Holdings provides products and solutions to customers in the cannabis and CBD industries, it has no direct involvement with the cannabis plant or any products that contain THC or CBD.

For more information, visit www.kushco.com or call (888)-920-5874

KushCo Holdings Contacts

Media Contact:
Anne Donohoe / Nick Opich
KCSA Strategic Communications
212-896-1265 / 212-896-1206
adonohoe@kcsa.com / nopich@kcsa.com

Investor Contact:
Phil Carlson / Elizabeth Barker
KCSA Strategic Communications
212-896-1233 / 212-896-1203
ir@kushco.com

SOURCE: KushCo Holdings, Inc.

ReleaseID: 550097

LOS ANGELES, CA / ACCESSWIRE / June 27, 2019 / Compare-autoinsurance.org has released a new blog post that provides more tips how to compare car insurance quotes online.

Online car insurance quotes are effective price comparison tools. It is recommended to get multiple quotes, from different providers and compare results. Now, clients can get multiple quotes really fast, simply by using http://compare-autoinsurance.org.

In order to get accurate and really useful estimates, a user must respect the following rules when comparing prices online:

Ask estimates for the same product. When a client compares different quotes from different websites, it’s essential for him to choose the same coverage levels, the same limits and the same extra options. Even a single difference between coverage options can lead to significant price differences.

Provide the same data on each quote. Again, discrepancies between used data may cause significant price differences. Online forms will ask about the car maker and model, year of production, safety devices, driving experience, traffic violations, ZIP code, deductibles and other info an insurer might find it relatable.

Provide realistic mileage estimates. Some questionnaires will ask the user to provide a number, while other questionnaires will ask to choose a limit. It’s important to choose the same range/limit on all questionnaires.

Do not try to hide the negative aspects of your profile. Aspects like traffic fines, at fault accidents, drunk driving, and even bad credit score have a significant impact on an insurance policy. Not adding these details when completing a questionnaire is pointless, as insurance companies already have access to all of this data.

Check all available discounts. Insurance companies offer different discounts for their drivers. The discounts can vary in value, and how long they last. For example, one insurer will provide a 15% discount for six months, while another insurer will provide a 10% discount for 12 months for the same service. Other insurance companies may offer discounts that other insurers don’t. It’s recommended to do careful research on the market.

Compare at least 3 online quotes. Multiple offers from different agencies are what the clients need to get a better idea of how his/her insurance rate might look like. It’s recommended to get at least 3 online quotes before deciding which insurer has the best policy.

“Comparing car insurance quotes will help you find fair prices and high-quality coverage. You can get free quotes on our website!” said Russell Rabichev, Marketing Director of Internet Marketing Company.

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

For more information, please visit http://compare-autoinsurance.org.

Contact: cgurgu@internetmarketingcompany.biz

SOURCE: Internet Marketing Company

ReleaseID: 550103

VANCOUVER, BC / ACCESSWIRE / June 27, 2019 / Megastar Development Corp. (“Megastar”, or the “Company”) (TSX-V: MDV; Frankfurt: M5QN), an early stage mineral exploration company focused on its properties in Oaxaca, Mexico, is pleased to announce that Robert Archer has joined its Board of Directors.

Mr. Archer has more than 35 years’ experience in the mining industry, working throughout North and South America. After having spent 15 years with major mining companies, Mr. Archer moved to the junior mining sector where he held several senior management positions. Mr. Archer co-founded Great Panther Mining Limited, a growth-oriented mid-tier precious metals producer, having served as President & CEO until August 2017 and currently remains on its Board of Directors. Mr. Archer also serves as CEO and sits on the Board of Newrange Gold Corp. (TSX-V: NRG), an exploration company with assets in the Western United States. Mr. Archer is a Professional Geologist (registered in British Columbia) and holds an Honours BSc from Laurentian University in Sudbury, Ontario.

“We would like to welcome Bob aboard,” said Dusan Berka, CEO of Megastar. “Bob’s more than 20 years’ experience in Mexico highlighted by his accomplishment of building Great Panther into the company it is today, will be a great asset, as Megastar begins its work to advance its Mexican projects. Familiarity with Mexico, what it takes to build companies from an early-stage and being well-known to investors in the junior market space, will all help our company as it furthers work on its properties. In addition, as a geologist, he will be a great compliment to David Jones, our geological leader in Oaxaca.”

“When introduced to Megastar and its properties in Oaxaca, I was immediately intrigued,” said Bob Archer. “After spending some time with David Jones, the Company’s senior technical leader and learning why these assets were secured by Megastar, I quickly understood the possibilities. I look forward to bringing my experience to the Board and assisting the management team to advance the Company and its Mexican assets.”

The Company wishes to announce the departure of Jonathan Rich from its Board of Directors. Mr. Rich served on the Company’s Board since 2012, having helped it transition to a company now focused on its Mexican assets. Megastar wants to thank Mr. Rich for his work and support to the Company.

Lastly, the Company has granted an aggregate of 1,850,000 incentive stock options (“the Options”) to members of its Board and management team. The Options are exercisable for a period of three years from the date of grant at a price $0.11 per share and vesting over a period of three years. The Options have been granted under and are governed by the terms of the Company’s incentive stock option plan.

ABOUT MEGASTAR DEVELOPMENT CORP.

Megastar Development Corp. is an emerging resource company engaged in the evaluation, acquisition and exploration of mineral properties in Canada and Mexico. Megastar has an Option to acquire 100% interest in three epithermal Au-Ag mineral properties in Oaxaca, Mexico. Megastar also owns 100% interest in Ralleau mineral property in Urban Barry District, Lebel-Sur-Quévilion area of Quebec, currently under 50% Option to DeepRock Minerals Exploration Inc. For further information, investors and shareholders are invited to visit the Company’s website at www.megastardevelopment.com or call the office at 604-681-1568, or toll free at 1-877-377-6222.

ON BEHALF OF THE BOARD OF DIRECTORS

“DUSAN BERKA”

Dusan Berka, P. Eng.
President & CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements:

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.

SOURCE: Megastar Development Corp.

ReleaseID: 550082